

Ref: 25-272

Freedom of Information Request

11 April 2025

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

We can confirm that we do hold the information you are requesting

I am researching the incidence and treatment of Haemophilia A across the UK. I would greatly appreciate if you could answer to the following questions.

Q1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease

Mild: 63

Moderate: 18 Severe: 86

- Q2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?
- Altuvoct 0
- **Advate** 19
- Adynovi *
- Elocta *
- Esperoct 15
- Factor Eight Inhibitor Bypass Activity (FEIBA) *
- Hemlibra (Emicizumab) Standalone 61
- Hemlibra (Emicizumab) in combination with any Factor VIII *
- NovoEight 0
- NovoSeven RT *
- **Nuwiq** 0
- **Obizur** 0
- Refacto AF *
- Any other products- Desmopressin *
- Hympavzi (Marstacimab) 0

• CEVENFACTA - 0

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, providers and Trusts may allow identification of patients and should not be published.

Q3. For patients treated with Advate in the last three months, please provide:

- The number of haemophilia A patients treated prophylactically *
- The number of haemophilia A patients treated for any other reason (e.g. surgery, ondemand, breakthrough bleeds) 17

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, providers and Trusts may allow identification of patients and should not be published.

Q4. In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY?

- Altuvoct 0
- Advate 10
- Adynovi *
- Elocta 0
- Esperoct 6
- Factor Eight Inhibitor Bypass Activity (FEIBA) 0
- Hemlibra (Emicizumab) Standalone 61
- Hemlibra (Emicizumab) in combination with any Factor VIII *
- NovoEight 0
- NovoSeven RT *
- **Nuwiq** 0
- **Obizur** 0
- Refacto AF 0
- Any other products 0
- Hympavzi (Marstacimab) 0

• CEVENFACTA - 0

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, providers and Trusts may allow identification of patients and should not be published.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer
University Hospitals Bristol and Weston NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click here.

Yours sincerely

Freedom of Information Team University Hospitals Bristol and Weston NHS Foundation Trust